Growth in Cell & Gene Therapy predicts a wave of demand for biomanufacturing space

As life-sciences employment grows in both major and emerging life-sciences markets, advancements in innovation are accelerating across the United States, according to JLL. Yet real estate development occurs on a much slower timeline and finding space appropriately equipped for large-scale research, development and production is crucial to success. This year, the Cell & Gene Therapy (CGT) industry is set to have its highest annual number of regulatory approvals of new gene therapy and gene-modified cell therapy products, meaning a limited space supply could pose speed to market challenges.

“This seismic transformation in the underlying fundamentals of biomanufacturing real estate is having a direct impact on the availability of space, as well as its design, architecture, engineering and financing,” said Roger Humphrey, president, JLL Life Sciences.

Cell therapy generally involves removing, modifying, then reintroducing modified live cells into a patient, whereas